Rosiglitazone or pioglitazone in type 2 diabetes?

BMJ (Online)

Volumn 339, Issue 7720, 2009, Pages 524-

  De Vries, Corinne S ^a   Russell Jones, David L ^b  

^a University of Bath   (United Kingdom)

^b UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMILORIDE; PIOGLITAZONE; ROSIGLITAZONE; SPIRONOLACTONE;

ACUTE HEART INFARCTION; CARDIOVASCULAR RISK; DEATH; DRUG SAFETY; DRUG TREATMENT FAILURE; EDITORIAL; HEART FAILURE; HUMAN; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

DIABETES MELLITUS, TYPE 2; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; MYOCARDIAL INFARCTION; RISK FACTORS; THIAZOLIDINEDIONES;

EID: 69949101465     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.b3076     Document Type: Editorial

References (12)

1. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. 2009. www.nice.org.uk/CG87ShortGuideline.
2. Juurlink DN, Gomes T, Lipscombe LL, Austin PC, Hux JE, Mamdani MM. Adverse cardiovascular events during treatment with pioglitazone and rosiglitazone: population based cohort study. BMJ 2009;339:b2942.[Abstract/Free Full Text]
3. Kahn SE, Haffner SM, Heise MA, Herman WH, Holman RR, Jones NP, et al. Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 2006;355:2427-2443 [Abstract/Free Full Text]
4. Stafylas PC, Sarafidis PA, Lasaridis AN. The controversial effects of thiazilodinediones on cardiovascular morbidity and mortality. Int J Cardiol 2009;131:298-304.[CrossRef][Web of Science][Medline]
5. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I, et al. Randomized, placebocontrolled trial of pioglitazone in nondiabetic subjects with non-alcoholic steatohepatitis. Gastroenterology 2008;135:1176-1184[CrossRef] [Web of Science][Medline]
6. Szapary PO, Bloedon LAT, Samaha FF, Duffy D, Wolfe ML, Soffer D, et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 2006;26:182-188[Abstract/Free Full Text] (Pubitemid 43732247)
7. Bodmer M, Meier C, Kraenzlin ME, Meier CR. Risk of fractures with glitazones: a critical review of the evidence to date. Drug Saf 2009;32:539-547[CrossRef][Medline]
8. Erdmann E, Wilcox RG. Weighing up the cardiovascular benefits of thiazolidinedione therapy: the impact of increased risk of heart failure. Eur Heart J 2008;29:12-20.[Abstract/Free Full Text]
9. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med 2007;147:578-581[Abstract/Free Full Text] (Pubitemid 351664507)
10. Lago RM, Singh PP, Nesto RW. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials. Lancet 2007;370:1129- 1136[CrossRef][Web of Science][Medline]
11. Habib ZA, Tzogias L, Havstad S, Wells K, Divine G, Lanear DE, et al. Relationship between thiazolidinedione use and cardiovascular outcomes and all-cause mortality among patients with diabetes: a time-updated propensity analysis. Pharmacoepidemiol Drug Saf 2009;18:437-447[CrossRef][Web of Science][Medline]
12. Nesto RW, Bell D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and the American Diabetes Association. Circulation 2003;108:2941-2948[Free Full Text] (Pubitemid 37517824)